Secukinumab: In psoriasis and beyond

被引：0
|
作者：
Bubna, Aditya K. [1 ]
Viplav, Vinayak [1 ]
机构：
[1] Katihar Med Coll, Dept Dermatol, Katihar 854106, Bihar, India
来源：
JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY | 2025年 / 22卷 / 01期
关键词：
hidradenitis suppurativa; off-label dermatologic indications; psoriasis; secukinumab; ORAL LICHEN-PLANUS; HIDRADENITIS SUPPURATIVA; PALMOPLANTAR PSORIASIS; PYODERMA-GANGRENOSUM; CONTROLLED-TRIAL; DOUBLE-BLIND; TH17; EFFICACY; THERAPY; SAFETY;
D O I：
10.4103/jewd.jewd_80_23
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (>= 6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Beh & ccedil;et's disease. This review will throw light on secukinumab's utility in psoriasis, as well as other dermatologic conditions.
引用
收藏
页码：1 / 12
页数：12
相关论文
共 50 条
  • [1] Secukinumab in the treatment of psoriasis: an update
    Reszke, Radomir
    Szepietowski, Jacek C.
    IMMUNOTHERAPY, 2017, 9 (03) : 229 - 238
  • [2] Safety of secukinumab in the treatment of psoriasis
    Blauvelt, Andrew
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (10) : 1413 - 1420
  • [3] Secukinumab (AIN457) for the treatment of psoriasis
    Lopez-Ferrer, Anna
    Vilarrasa, Eva
    Puig, Lluis
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (11) : 1177 - 1188
  • [4] Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
    Kivelevitch, Dario
    Amin, Sima
    Menter, Alan
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2019, 12 : 249 - 253
  • [5] Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
    Bruin, Gerard
    Loesche, Christian
    Nyirady, Judit
    Sander, Oliver
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (07) : 876 - 885
  • [6] Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study
    Galluzzo, Marco
    Talamonti, Marina
    Atzori, Laura
    Bardazzi, Federico
    Campanati, Anna
    Di Cesare, Antonella
    Diotallevi, Federico
    Flori, Maria Laura
    Mugheddu, Cristina
    Offidani, Annamaria
    Piaserico, Stefano
    Russo, Filomena
    Sacchelli, Lidia
    Bianchi, Luca
    Prignano, Francesca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (04) : 547 - 554
  • [7] Scalp psoriasis: report of efficient treatment with secukinumab
    Pistone, Giuseppe
    Tilotta, Giovanna
    Gurreri, Rosario
    Curiale, Salvatrice
    Bongiorno, Maria Rita
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 : 14 - 16
  • [8] Secukinumab for treating plaque psoriasis
    Rothstein, Brooke
    Gottlieb, Alice
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (01) : 119 - 128
  • [9] A review of secukinumab in psoriasis treatment
    Berg, Scott H.
    Balogh, Esther A.
    Ghamrawi, Rima, I
    Feldman, Steven R.
    IMMUNOTHERAPY, 2021, 13 (03) : 201 - 216
  • [10] Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab
    Pizzatti, Laura
    Mugheddu, Cristina
    Sanna, Silvia
    Atzori, Laura
    Rongioletti, Franco
    DERMATOLOGIC THERAPY, 2020, 33 (03)
12345